Key result
Bone marrow mesenchymal stem cells for tissue engineered pulmonary valves represent a promising approach for valve replacement that is currently countered by realistic clinical concerns.
This paper discusses the expectations and concerns surrounding the use of bone marrow mesenchymal stem cells for tissue-engineered pulmonary valves.
Raises legitimate concerns for valve tissue engineering; leaves open clinical translation pending rigorous trials.
Introduction Valvular heart disease is a significant cause of morbidity and mortality; annually, there are over 100,000 valve replacements in the US [1]. Heart valve tissue engineering has captured the popular imagination of investigators and patients alike. Expectation and hope is however countered by realistic and legitimate concerns [1-9]. The fundamental
No takes yet. Share an insight, caveat, or question.
Asumda et al. (2014) studied this question. Bone marrow mesenchymal stem cells for tissue engineered pulmonary valves represent a promising approach for valve replacement that is currently countered by realistic clinical concerns.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: